Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 191.35
1 948.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Note Receivable
Sun Pharmaceutical Industries Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Note Receivable
₹10.9B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-2%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Note Receivable
₹3.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Note Receivable
₹3.3B
|
CAGR 3-Years
1 392%
|
CAGR 5-Years
45%
|
CAGR 10-Years
0%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Note Receivable
₹1.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-10%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Note Receivable
₹2.3B
|
CAGR 3-Years
87%
|
CAGR 5-Years
18%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Note Receivable
₹1.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sun Pharmaceutical Industries Ltd
Glance View
Sun Pharmaceutical Industries Ltd. is a leading global pharmaceutical company based in India, renowned for its commitment to producing high-quality generic and specialty medicines. Founded in 1983, Sun Pharma has evolved into one of the largest pharmaceutical companies in India and the fifth largest globally in the generic market. With a robust portfolio that encompasses various therapeutic areas, including cardiology, psychiatry, neurology, and oncology, the company has built a solid reputation for innovation and reliability. A strong emphasis on research and development drives Sun Pharma’s growth, helping it to continuously expand its product offerings and tap into new markets, as evidenced by its strategic acquisitions and partnerships over the years. For investors, Sun Pharmaceutical presents a compelling opportunity, underpinned by its solid financial performance and a forward-looking strategic vision. The company's extensive presence in over 150 countries combined with a diverse portfolio fuels its competitive edge in the global pharmaceutical landscape. With a solid track record of profitability and a commitment to enhancing shareholder value, Sun Pharma is well-positioned to capture growth in emerging markets and capitalize on advancements in biologics and complex generics. Moreover, the company’s focus on sustainability and ethical practices resonates in an increasingly socially conscious investment environment, making it an appealing prospect for investors looking to diversify their portfolios while supporting a responsible industry leader.
See Also
What is Sun Pharmaceutical Industries Ltd's Note Receivable?
Note Receivable
10.9B
INR
Based on the financial report for Sep 30, 2024, Sun Pharmaceutical Industries Ltd's Note Receivable amounts to 10.9B INR.
What is Sun Pharmaceutical Industries Ltd's Note Receivable growth rate?
Note Receivable CAGR 10Y
-2%
Over the last year, the Note Receivable growth was -49%. The average annual Note Receivable growth rates for Sun Pharmaceutical Industries Ltd have been -35% over the past three years , -18% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet
